论文部分内容阅读
1 临床资料 全部病例均为住院患者,病人诊断符合1995年北京全国传染病寄生虫病学术会议的病毒性肝炎诊断标准。患者以往半年内无抗病毒药物及免疫调节剂应用史,男15例,女10例,年龄17～60岁,平均43岁,无心、肾、内分泌、造血系统疾病、精神病史及妊娠。随机分A、B两组。分别应用IFN—α2a和α2b,第一周300万U/d肌注,以后每周隔日一次,连续用药3个月。 主要观察乙肝病毒标志物HBV—IgM,HBV—DNA及肝功能变化。HBV—IgM用ELISA法(上海科华试剂),HBV—DNA用PCR法(上海复星试剂),肝功、ALT用酶速率法。
1 Clinical data All cases were hospitalized patients diagnosed in line with the 1995 Beijing National Conference on Infectious Diseases Parasitic Diseases diagnostic criteria for viral hepatitis. In the past six months, there was no history of application of antiviral drugs and immunomodulators. There were 15 males and 10 females, aged from 17 to 60 years with an average of 43 years of age, without heart, kidney, endocrinology, hematopoietic system diseases, psychiatric history and pregnancy. Randomly divided A, B two groups. IFN-α2a and α2b were administered respectively, with 3 million U / d intramuscular injection in the first week, followed by once every other week for 3 months. The main observation of hepatitis B virus markers HBV-IgM, HBV-DNA and liver function changes. HBV-IgM by ELISA (Shanghai Kehua reagent), HBV-DNA by PCR method (Shanghai Fosun reagent), liver function, ALT enzyme rate method.